Platelet-Rich Plasma Composition for Sensorineural Hearing Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sensorineural hearing loss and tinnitus are ineffective, particularly for severe cases, and lack therapeutic options for tinnitus.
Innovation Solution
A pharmaceutical composition and method utilizing platelet-rich plasma (PRP) administered to the tympanic cavity, which can be incubated to increase viscosity for prolonged contact with inner ear nerve cells, potentially regenerating them, and combined with other known effective compositions like dexamethasone for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for sensorineural hearing loss and tinnitus, then current standard care is provided, but treatment effectiveness is insufficient especially for severe cases
Solution Approach 1:
The patent changes the chemical composition parameters by introducing platelet-rich plasma containing specific growth factors (PDGF, TGF-beta, VEGF) and administering it in specific dosages (0.5-5 mL per ear) to achieve therapeutic effects that conventional treatments cannot provide for sensorineural hearing loss and tinnitus
Solution Approach 2:
The patent combines platelet-rich plasma with other pharmaceutical compositions (such as dexamethasone, vitamins B12, B6, B1, and amino acids) to create a composite therapeutic formulation that enhances treatment effectiveness and provides multiple therapeutic mechanisms simultaneously
2Duration of action of moving object
If PRP is incubated to increase viscosity, then contact time with inner ear nerve cells is prolonged, but administration complexity increases
Solution Approach 1:
The patent applies preliminary action by incubating the platelet-rich plasma at room temperature for 1-40 minutes before administration to increase its viscosity, ensuring that the plasma will remain in contact with the inner ear nerve cells for a prolonged period (5-20 minutes or longer) after injection, thereby maximizing therapeutic effect
Solution Approach 2:
The patent uses the patient's own platelet-rich plasma (autologous PRP) prepared from their own blood, copying the body's natural healing mechanisms and growth factors to treat the hearing loss and tinnitus, which reduces immunogenicity and enhances compatibility
Data Source
AI summary
Provided are a pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma, and a method of preventing or treating sensorineural hearing loss or tinnitus using the same.